In fact, blocking the KIR2DL5/PVR interaction with monoclonal antibodies has been shown to enhance NK cell-mediated cytotoxicity against PVR+ tumors and reduce tumor growth, thereby improving overall survival in humanized tumor models (Ren et al., 2022). The gene discussed is PVR; the disease is neoplasm.